المؤلفون: N. S. Sergeeva, T. A. Karmakova, V. V. Savchina, T. I. Deshkina, E. Yu. Karpenko, L. V. Bolotina, I. I. Alentov, N. V. Marshutina, A. A. Fedenko

المصدر: Сибирский онкологический журнал, Vol 22, Iss 4, Pp 44-54 (2023)

مصطلحات موضوعية: kidney injury molecule 1 (kim-1), chemotherapy, cisplatin, nephrotoxicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.siboncoj.ru/jour/article/view/2678; https://doaj.org/toc/1814-4861; https://doaj.org/toc/2312-3168

URL الوصول: https://doaj.org/article/fb4d054817e74b32b8619e069c92407c

المؤلفون: P. V. Golubev, L. V. Bolotina, A. R. Gevorkov, T. I. Deshkina

المصدر: Issledovaniâ i Praktika v Medicine, Vol 10, Iss 3, Pp 32-42 (2023)

مصطلحات موضوعية: smoking, induction chemotherapy, human papillomavirus, squamous cell cancer, Medicine

وصف الملف: electronic resource

Relation: https://www.rpmj.ru/rpmj/article/view/924; https://doaj.org/toc/2410-1893

URL الوصول: https://doaj.org/article/62fe4f003b864c28b1f6409432c07a37

المؤلفون: P. V. Golubev, L. V. Bolotina, A. R. Gevorkov, T. I. Deshkina, A. V. Boyko, A. D. Kaprin

المصدر: Сибирский онкологический журнал, Vol 22, Iss 2, Pp 26-33 (2023)

مصطلحات موضوعية: squamous cell carcinoma, oropharyngeal carcinoma, human papillomavirus, induction chemotherapy, toxicity, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.siboncoj.ru/jour/article/view/2525; https://doaj.org/toc/1814-4861; https://doaj.org/toc/2312-3168

URL الوصول: https://doaj.org/article/ac1d2f1dfc6144ef9b51e377dbfe3812

المؤلفون: L. V. Bolotina, A. L. Kornietskaya, A. A. Kachmazov, N. S. Prizova, A. A. Paichadze, T. V. Ustinova, T. I. Deshkina, S. F. Evdokimova

المصدر: Медицинский совет, Vol 0, Iss 9, Pp 179-184 (2022)

مصطلحات موضوعية: brca-associated breast cancer, parp inhibitors, olaparib, her2neu amplification, germline mutation, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/6931; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/eb29d7aee9514c7e82e7f35e8cd03be6

المؤلفون: T. I. Deshkina, L. V. Bolotina, A. R. Gevorkov, A. V. Boyko, V. S. Surkova, M. V. Sedova, A. P. Polyakov, A. L. Kornietskaya, A. A. Fedenko

المصدر: Опухоли головы и шеи, Vol 11, Iss 4, Pp 110-118 (2022)

مصطلحات موضوعية: neuroendocrine cancer, sinonasal carcinoma, maxillary sinus cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://ogsh.abvpress.ru/jour/article/view/723; https://doaj.org/toc/2222-1468; https://doaj.org/toc/2411-4634

URL الوصول: https://doaj.org/article/c981d3e9e7fc4b879907b37528889de4

المؤلفون: V. D. Levina, M. G. Poltavskaya, P. Sh. Chomakhidze, A. A. Meshcheryakov, L. V. Bolotina, T. I. Deshkina, D. S. Valiulina, A. N. Gerasimov, O. V. Andreeva, A. A. Shmeleva, Z.Z.A. Fashafsha, A. R. Levshina, V. P. Sedov

المصدر: Российский кардиологический журнал, Vol 27, Iss 11 (2022)

مصطلحات موضوعية: cardiotoxicity, anthracyclines, chemotherapy, left ventricular dysfunction, troponin, breast cancer, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://russjcardiol.elpub.ru/jour/article/view/5210; https://doaj.org/toc/1560-4071; https://doaj.org/toc/2618-7620

URL الوصول: https://doaj.org/article/ea5566c3d2754d0da71b34bd21705923

المؤلفون: L. V. Bolotina, T. I. Deshkina, A. L. Kornietskaya, S. A. Kravtsov, T. V. Ustinova, A. A. Paychadze, A. D. Kaprin, А. А. Fedenko

المصدر: Опухоли головы и шеи, Vol 10, Iss 2, Pp 10-21 (2020)

مصطلحات موضوعية: squamous cell carcinoma of the head and neck, platinum-based chemotherapy, immuno-oncological drugs, nivolumab, pembrolizumab, 1st line drug therapy, pd-l1 expression, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://ogsh.abvpress.ru/jour/article/view/522; https://doaj.org/toc/2222-1468; https://doaj.org/toc/2411-4634

URL الوصول: https://doaj.org/article/b048da499da94939b7645edc7f4ba6eb

المؤلفون: L. V. Bolotina, T. I. Deshkina

المصدر: Опухоли женской репродуктивной системы, Vol 0, Iss 1, Pp 42-48 (2014)

مصطلحات موضوعية: breast cancer, adjuvant chemotherapy, immunohistochemical subtypes, docetaxel, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://ojrs.abvpress.ru/ojrs/article/view/10; https://doaj.org/toc/1994-4098; https://doaj.org/toc/1999-8627

URL الوصول: https://doaj.org/article/cbc62d2c3baf4b0eace54163ef8aeace

المؤلفون: A. L. Kornietskaya, L. V. Bolotina, S. F. Evdokimova, N. S. Prizova, T. V. Ustinova, T. I. Deshkina, A. A. Fedenko, А. Л. Корниецкая, Л. В. Болотина, С. Ф. Евдокимова, Н. С. Призова, Т. В. Устинова, Т. И. Дешкина, А. А. Феденко

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 172-177 ; Медицинский Совет; № 11 (2023); 172-177 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: таргетная терапия, PARP inhibitors, olaparib, BRCA1/2 mutation, burdened familial history, maintenance therapy, pancreatic cancer, targeted therapy, PARP-ингибиторы, олапариб, мутация BRCA1/2, отягощенный семейный анамнез, поддерживающая терапия, рак поджелудочной железы

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7702/6834; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.; Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.; Sohal D.P., Mangu P.B., Khorana A.A., Shah M.A, Philip P.A., O’Reilly E.M. et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(23):2784–2796. https://doi.org/10.1200/JCO.2016.67.1412.; Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. https://doi.org/10.1056/NEJMoa1011923.; Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369.; Burris H.A. 3rd, Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413. https://doi.org/10.1200/JCO.1997.15.6.2403.; Swayden M., Iovanna J., Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype. Heliyon. 2018;4(12):e01055. https://doi.org/10.1016/j.heliyon.2018.e01055.; Klein A.P. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51(1):14–24. https://doi.org/10.1002/mc.20855.; Klein A.P., Brune K.A., Petersen G.M., Goggins M., Tersmette A.C., Offerhaus G.J. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–2638. https://doi.org/10.1158/0008-5472.can-03-3823.; Hiripi E., Lorenzo Bermejo J., Li X., Sundquist J., Hemminki K. Familial association of pancreatic cancer with other malignancies in Swedish families. Br J Cancer. 2009;101(10):1792–1797. https://doi.org/10.1038/sj.bjc.6605363.; Schneider R., Slater E.P., Sina M., Habbe N., Fendrich V., Matthäi E. et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer. 2011;10(2):323–330. https://doi.org/10.1007/s10689-010-9414-x.; Goggins M., Overbeek K.A., Brand R., Syngal S., Del Chiaro M., Bartsch D.K. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7–17. https://doi.org/10.1136/gutjnl-2019-319352.; Gardiner A., Kidd J., Elias M.C., Young K., Mabey B., Taherian N. et al. Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes. J Natl Cancer Inst. 2022;114(7):996–1002. https://doi.org/10.1093/jnci/djac069.; Vietri M.T., D’Elia G., Caliendo G., Albanese L., Signoriello G., Napoli C., Molinari A.M. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation. Genes (Basel). 2022;13(2):321. https://doi.org/10.3390/genes13020321.; Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R. et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002;62(13):3789–3793. https://pubmed.ncbi.nlm.nih.gov/12097290/; George A., Kaye S., Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–296. https://doi.org/10.1038/nrclinonc.2016.191.; Li S., Silvestri V., Leslie G., Rebbeck T.R., Neuhausen S.L., Hopper J.L. et al. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol. 2022;40(14):1529–1541. https://doi.org/10.1200/JCO.21.02112; Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. https://doi.org/10.1038/nature03445.; Kindler H.L., Hammel P., Reni M., Van Cutsem E., Macarulla T., Hall M.J. et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022;40(34):3929–3939. https://doi.org/10.1200/JCO.21.01604.; Axilbund J.E., Argani P., Kamiyama M., Palmisano E., Raben M., Borges M. et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009;8(2):131–135. https://doi.org/10.4161/cbt.8.2.7136.; Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B. et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95(3):214–221. https://doi.org/10.1093/jnci/95.3.214.; Couch F.J., Johnson M.R., Rabe K.G., Brune K., de Andrade M., Goggins M. et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(2):342–346. https://doi.org/10.1158/1055-9965.EPI-06-0783.; https://www.med-sovet.pro/jour/article/view/7702

الاتاحة: https://www.med-sovet.pro/jour/article/view/7702
https://doi.org/10.21518/ms2023-231

المؤلفون: T. I. Deshkina, L. V. Bolotina, P. V. Golubev, I. E. Gabuniya, M. S. Ruban, A. A. Fedenko, A. D. Kaprin, Т. И. Дешкина, Л. В. Болотина, П. В. Голубев, И. Э. Габуния, М. С. Рубан, А. А. Феденко, А. Д. Каприн

المصدر: Malignant tumours; Том 13, № 3 (2023); 29-36 ; Злокачественные опухоли; Том 13, № 3 (2023); 29-36 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: де-эскалация, neoadjuvant therapy, HER2‑positive status, de-escalation, неоадъювантная терапия, HER2-позитивный статус

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1166/809; Состояние онкологической помощи населению России в 2021 г, под редакцией А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. Москва 2022 г, с. 23–25.; Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010 Nov; 28 (9) : 963–8. doi:10.3109/07357907.2010.496759. PMID: 20690807; PMCID: PMC5094051.; Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer : Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177–182.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New Engl. J. Med. 2001, 344, 783–792.; Клинические рекомендации «Рак молочной железы» Общероссийский национальный союз «Ассоциация онкологов России» • Общероссийская общественная организация «Российское общество клинической онкологии» • Общероссийская общественная организация «Российское общество онкомаммологов», 2021 г.; Тюляндин С. А., Жукова Л. Г., Королева И. А., Пароконная А. А., Семиглазова Т. Ю., Стенина М. Б. и соавт. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2021 (том 11). 09.; Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9; 393 (10175) : 986]. Lancet. 2014; 384 (9938) : 164–172. doi:10.1016/S0140-6736(13)62422-8.; von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30 (15) : 1796–1804. doi:10.1200/JCO. 2011.38.8595.; Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer : results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011; 29 (25) : 3351–3357. doi:10.1200/ JCO.2010.31.4930.; Broglio KR, Quintana M, Foster M, et al. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes : A Meta-Analysis. JAMA Oncol. 2016; 2 (6) : 751–760. doi:10.1001/jamaoncol. 2015.6113.; von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019; 380 (7) : 617–628. doi:10.1056/NEJMoa1814017.; Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH) : follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort [published correction appears in Lancet Oncol. 2018 Dec; 19 (12) : e667]. Lancet Oncol. 2014; 15 (6) : 640–647. doi:10.1016/S1470-2045(14)70080-4.; Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13 (1) : 25–32. doi:10.1016/S1470-2045(11)70336-9.; Untch M, Jackisch C, Schneeweiss A, et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer : GBG 69-GeparSepto. J Clin Oncol. 2019; 37 (25) : 2226–2234. doi:10.1200/JCO. 18.01842.; Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer : a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24 (9) : 2278–2284. doi:10.1093/ annonc/mdt182.; van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19 (12) : 1630–1640. doi:10.1016/S1470-2045(18)30570-9.; Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer : TBCRC 006. J Clin Oncol. 2013; 31 (14) : 1726–1731. doi:10.1200/JCO. 2012.44.8027.; Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, et al.; Translational Breast Cancer Research Consortium. TBCRC023 : A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 Feb 15; 26 (4) : 821–827. doi:10.1158/1078-0432.CCR-19-0851. Epub 2019 Oct 29. PMID: 31662331.; Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA) : an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr; 18 (4) : 545–554. doi:10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24. PMID: 28238593.; Guarneri V, Dieci MV, Bisagni G, et al. De-escalated therapy for HR + / HER2 + breast cancer patients with Ki67 response after 2-week letrozole : results of the PerELISA neoadjuvant study. Ann Oncol. 2019; 30 (6) : 921–926. doi:10.1093/annonc/mdz055.; Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, Zambetti M, Frassoldati A, De Fato R, Valagussa P, Viale G. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2) : an exploratory, open-label, phase 2 study. Lancet Oncol. 2018 Feb; 19 (2) : 249–256. doi:10.1016/S1470-2045(18)30001-9. Epub 2018 Jan 8. PMID: 29326029.; Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE) : a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018; 19 (1) : 115–126. doi:10.1016/S1470-2045(17) 30716–7.; Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer : Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019; 37 (25) : 2206–2216. doi:10.1200/JCO. 19.00882.; Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC) : final analysis of the WSG-ADAPT HER2 +/HR- phase II trial : efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel [published correction appears in Ann Oncol. 2022 Mar; 33 (3) : 355]. Ann Oncol. 2017; 28 (11) : 2768–2772. doi:10.1093/annonc/mdx494.; Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2 + / HR-) : survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022; 23 (5) : 625–635. doi:10.1016/S1470-2045(22)00159-0.; Pérez-García JM, Gebhart G, Ruiz Borrego M, et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021; 22 (6) : 858–871. doi:10.1016/S1470- 2045 (21) 00122-4.; https://www.malignanttumors.org/jour/article/view/1166

الاتاحة: https://www.malignanttumors.org/jour/article/view/1166
https://doi.org/10.18027/2224-5057-2023-13-3-29-36

المؤلفون: V. D. Levina, M. G. Poltavskaya, V. P. Sedov, P. Sh. Chomakhidze, L. V. Bolotina, T. I. Deshkina, M. D. Kuklina, A. A. Meshcheryakov, A. G. Komarova, Z. A. Kuli-Zade, A. N. Gerasimov

المصدر: Medical alphabet. :19-26

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::719eceb7a57a1bc87806f1b0c0c125bc
https://doi.org/10.33667/2078-5631-2022-33-19-26

المؤلفون: E. V. Lubennikova, A. L. Kornietskaya, N. S. Dorofeeva, E. I. Rossokha, E. V. Markarova, I. V. Yudina, I. Y. Bazaeva, L. V. Bolotina, T. I. Deshkina, Ya. A. Zhulikov, E. V. Stasenko, T. V. Ustinova, A. S. Tsareva, E. V. Artamonova

المصدر: Meditsinskiy sovet = Medical Council. :21-29

مصطلحات موضوعية: General Medicine

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9f81122c67dba96ceb4f8aa960dd83f3
https://doi.org/10.21518/2079-701x-2022-16-22-21-29

المؤلفون: L. A. Koroleva, T. I. Deshkina, A.R. Gevorkov, Paychadze Aa, A. L. Kornietskaya, L. V. Bolotina, A. P. Polyakov, Sedova Mv

المصدر: Biomedical Journal of Scientific & Technical Research. 26

مصطلحات موضوعية: Nasal cavity, medicine.medical_specialty, Maxillary sinus, business.industry, medicine.medical_treatment, Induction chemotherapy, General Medicine, Malignancy, medicine.disease, Radiation therapy, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Paranasal sinuses, 030220 oncology & carcinogenesis, otorhinolaryngologic diseases, Carcinoma, Medicine, Radiology, 030223 otorhinolaryngology, business, Survival rate

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9ba1d60dea07baac7efb7d4cdb0f82db
https://doi.org/10.26717/bjstr.2020.26.004298

المؤلفون: T. I. Deshkina, P.V. Golubev, A.R. Gevorkov, L. V. Bolotina

المصدر: Onkologiya. Zhurnal imeni P.A.Gertsena. 10:47

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Oropharyngeal squamous cell carcinoma, Current (fluid), business, De-escalation, Volume (compression)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b6364ae2ede622bcf4b16c99d36b21c7
https://doi.org/10.17116/onkolog20211003147

المؤلفون: A. L. Kornietskaya, Andrey Kaprin, L. V. Bolotina, T. I. Deshkina

المصدر: Onkologiya. Zhurnal imeni P.A.Gertsena. 6:44

مصطلحات موضوعية: Oncology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Internal medicine, medicine, Treatment strategy, Basal cell, Head and neck, business, 030218 nuclear medicine & medical imaging

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::989682afc81bd4497c0c98a3cb568817
https://doi.org/10.17116/onkolog20176544-49

المؤلفون: D. D. Sobolev, L. V. Kramskaya, A. B. Ryabov, L. V. Bolotina, T. I. Deshkina

المصدر: Onkologiya. Zhurnal imeni P.A.Gertsena. 4:52

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Combined treatment, business.industry, Adjuvant chemotherapy, Perioperative chemotherapy, Internal medicine, Locally advanced, Medicine, Cancer, business, medicine.disease

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a824896868fb3228316e6f40031a0586
https://doi.org/10.17116/onkolog20154452-56